Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluarix Clear all
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

NCT00772889
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2186877A, GSK Biologicals' Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
9
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 19, 2026, 11:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Study to Describe Pediatric Influenza Vaccine Coverage

NCT00639418
View directory record Official record
Conditions
Healthy
Interventions
Influenza vaccination
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months and older
Enrollment
147,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
187
States / cities
Birmingham, Alabama • Daphne, Alabama • Montgomery, Alabama + 167 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 19, 2026, 11:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

NCT06848309
View directory record Official record
Conditions
Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions
Bronchoscopy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 19, 2026, 11:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

NCT07159763
View directory record Official record
Conditions
Influenza
Interventions
MK-1406, Placebo
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
120
States / cities
Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 19, 2026, 11:45 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Multilevel Intervention of COVID-19 Vaccine Uptake Among Latinos

NCT06156228
View directory record Official record
Conditions
Vaccine Hesitancy
Interventions
Multilevel Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

NCT00192192
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

NCT04074928
View directory record Official record
Conditions
Influenza, Human, Virus Diseases
Interventions
QIVc, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 47 Months
Enrollment
2,414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
47
States / cities
Mobile, Alabama • Anaheim, California • Downey, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 19, 2026, 11:45 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Immune Responses to Influenza Vaccination

NCT03346772
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Influenza vaccination
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 11:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

NCT03743688
View directory record Official record
Conditions
Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions
Influenza Vaccine Recipients
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

NCT01196988
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
14
States / cities
Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

NCT03615482
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, QIV, Matching Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

NCT01525004
View directory record Official record
Conditions
Pediatric Solid Organ Transplant Patients
Interventions
High-Dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
3 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 19, 2026, 11:45 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

NCT01967238
View directory record Official record
Conditions
Healthy
Interventions
IM Pneumococcal, meningococcal, or flu vaccine
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 11:45 PM EDT
Completed No phase listed Observational

QuickVue Influenza A + B Test Field Study

NCT03417869
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
QuickVue Influenza A+B
Device
Lead sponsor
Quidel Corporation
Industry
Eligibility
Not listed
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, New York • Belton, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 19, 2026, 11:45 PM EDT
Terminated Phase 1 Interventional

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

NCT01695733
View directory record Official record
Conditions
Neoplasms
Interventions
trivalent influenza vaccine
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Chronic CMV Infection on Influenza Vaccine Responses

NCT02134184
View directory record Official record
Conditions
Cytomegalovirus Infections, Influenza
Interventions
Fluzone® 2012-2013 Formula NDC No 498281-012-50
Biological
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 19, 2026, 11:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Home Testing of Respiratory Illness

NCT04245800
View directory record Official record
Conditions
Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection, Respiratory Tract Infections
Interventions
Not listed
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
5,233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 19, 2026, 11:45 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

NCT06229392
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Triple Negative
Interventions
Fluzone Quadrivalent
Biological
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 19, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

NCT02206464
View directory record Official record
Conditions
Influenza
Interventions
A/Shanghai/02/2013 (H7N9) MIV, VRC-FLUDNA071-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 19, 2026, 11:45 PM EDT